A fully integrated specialty pharma company, Midatech Pharma is rapidly progressing the development of three lead R&D programs. They have developed three proprietary drug delivery technologies (Q-Sphera, Gold Nano Particle and Nano Inclusion) to improve and expand the therapeutic potential of validated drug products. At the same time Midatech has built a US commercial unit focused on supportive care products.
We look in more detail at the three lead programs Q-Octreotide, MTX110 and MTD119 below. Midatech's commercial business in the US is selling in-licensed products for supportive cancer care. This specialty pharma business brought in revenue of about £7m in 2017 and is expected to be profitable since 1H 2018. This division will also represent Midatech's commercial infrastructure for the launch of the ongoing pipeline programs.